U.S. Influenza Vaccines Market Is Expected To Witness A Cagr Of 15.9% Over The Forecast Period 2018 To 2026 By Key Players Sanofi Pasteur, Seqirus Vaccines Ltd, GlaxoSmithKline Plc, and Medimmune

Influenza commonly referred as flu is a contagious respiratory illness caused by influenza virus. The virus can cause mild to severe illness, resulting in serious outcomes such as hospitalization or death. Geriatric population, pregnant women, and people with chronic health conditions are at high risk of serious flu complications. Influenza virus is responsible for seasonal epidemic events and are classified into two types of influenza virus, including A and B. The influenza vaccines market is expected to gain significant traction as number of manufacturers are increasing the production capacity of vaccines for use in the U.S. market for the 2017–2018 influenza season using the innovative technologies such as egg-based, cell-based, and recombinant technologies.

Get PDF Brochure of Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/1127

Market Dynamics

The major factors driving growth of the U.S. influenza vaccines market include rapid advancements in technology for development of new vaccines such as recombinant and cell-based technologies, resulting in increasing production of the vaccines. Influenza flu vaccination have the potential to reduce the risk of flu-associated hospitalization among children and adults. According to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented an around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S.

Moreover, the collaborative efforts of various government bodies such as U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) with the private sector has led to development of improved influenza vaccine technologies in the U.S. This in turn, has improved influenza pandemic preparedness in the country. Also, National Institute of Allergy and Infectious Disease (NIAID) supports research efforts to improve seasonal flu vaccine strain selection and vaccine effectiveness. However, high cost of manufacturing and complexity of the production process due to inherent variability of the viral strains are the major factors hindering growth of the U.S. influenza vaccines market.

Key features of the study:

-This report provides in-depth analysis of U.S. influenza vaccines market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
-It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
-This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
-It profiles leading players in the U.S. influenza vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
-Key companies covered as a part of this study include Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune

Request For Customization Of This Report : https://www.coherentmarketinsights.com/insight/request-customization/1127

Detailed Segmentation:

U.S. Influenza Vaccines Market, By Vaccine Type:
Trivalent Vaccines
Quadrivalent Vaccines

U.S. Influenza Vaccines Market, By Virus Type:
Influenza Virus Type A
Influenza Virus Type B

U.S. Influenza Vaccines Market, By Age Group:
Pediatrics
Adults

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.